According to the recent findings regarding the therapeutic impact of co-mutations on the prognosis of KRAS-mutant NSCLC patients, in particular SMARCA4 and STK11 being associated with worse prognosis and TP53 being correlated with improved immune response and OS. Here, SMARCA4 is linked to non-small cell lung carcinoma.